

ASX Announcement

11 June 2024

5th patient is treated with the OncoSil™ device in PANCOSIL trial

In total 5 patients have now been treated with the OncoSil™ device in the Netherlands-based PANCOSIL Investigator Initiated Clinical Trial

Key Highlights

- ✓ 5th patient has been treated in the ongoing PANCOSIL Investigator Initiated Clinical Trial.
- ✓ PANCOSIL is a Netherlands-based Investigator Initiated Clinical Trial conducted at AMC Medical Centre in Amsterdam in collaboration with OncoSil Medical.
- ✓ This Trial is testing the safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) with the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer.
- ✓ In all, 20 patients will be treated with the OncoSil™ device by percutaneous application over the course of the PANCOSIL Trial.
- ✓ The next step is a protocol amendment to remove the requirement for general anesthesia, obtaining ethics committee approval and commence treating patients under conscious sedation.

Sydney, Australia – 11 June 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to provide an update on the PANCOSIL Clinical Trial, a Netherlands-based Investigator Initiated Clinical Trial conducted at AMC Medical Centre in Amsterdam in collaboration with OncoSil Medical.

The PANCOSIL Trial is designed to assess the safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) using the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer. The trial aims to treat a total of 20 patients with the OncoSil™ device through percutaneous application.

On 28 May 2024, the fifth patient in the PANCOSIL Trial received treatment with the OncoSil™ device. This milestone is an important step towards understanding the potential benefits of this innovative treatment approach.

The next step in the PANCOSIL Trial involves a protocol amendment to remove the requirement for mandatory general anesthesia. This amendment aims to allow treatment under conscious sedation, subject to approval from the Ethics Committee. The proposed change is expected to enhance patient comfort and expedite patient recruitment into the trial.

OncoSil Medical Ltd remains committed to advancing the treatment of locally advanced pancreatic cancer and looks forward to providing further updates as the PANCOSIL Trial progresses.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043</p>	<p>Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699</p>
--	--	--

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>